Table 3 |
||||||
|
Clinical characteristics of the patients with a high iron score and treatment-related death AML indicates acute myeloid leukemia |
||||||
|
Demographics |
Disease |
Donor |
Conditioning |
Iron Score (pRBCs) |
Survival |
Cause of Death |
|
|
||||||
|
53 y/o male |
ALL (CR2) |
MRD |
Cytoxan/TBI |
2 (45) |
16 days |
Clostridial sepsis |
|
24 y/o female |
AML (CR1) |
MUD |
Busulfan/Cytoxan |
2 (42) |
26 days |
Septic shock (culture negative) |
|
48 y/o female |
AML (CR2) |
MRD |
Cytoxan/TBI |
3 (38) |
8 days |
Pneumonia/ARDS |
|
62 y/o female |
Refractory AML |
MRD |
Non-ablative |
2 (43) |
50 days |
CMV pneumonia |
|
50 y/o female |
MDS |
MUD |
Cytoxan/TBI |
3 (35) |
6 days |
Pneumonia/ARDS |
|
32 y/o male |
AML (CR1) |
MRD |
Cytoxan/TBI |
2 (58) |
13 days |
Septic shock (culture negative) |
|
49 y/o female |
Aplastic anemia |
MUD |
Cytoxan/TBI |
2 (30) |
27 days |
Gram-negative sepsis |
|
|
||||||
|
ALL, acute lymphoblastic leukemia; MDS myelodysplastic syndrome; MRD matched related donor; MUD matched unrelated donor; TBI total body irradiation; ARDS acute respiratory distress syndrome. |
||||||
|
Storey et al. Journal of Hematology & Oncology 2009 2:44 doi:10.1186/1756-8722-2-44 |
||||||
